Melanoma
News and reporting on melanoma.
Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test
The gene expression profile assay is meant to aid dermatopathologists in characterizing difficult-to-diagnose melanocytic lesions.
Castle Biosciences Awarded VA Supply Contract for Melanoma Test
The company said the contract will provide greater access to its DecisionDx-Melanoma gene expression profile test for veterans and active duty military.
Germline Loss-of-Function Variants in ATM Gene May Contribute to Melanoma Predisposition
Individuals with melanoma were more likely than controls to harbor loss-of-function variants or VUS, according to a newly published study.
Integrated Tumor, Microbiome Features Influence Immunotherapy Combo Effects in Advanced Melanoma
Gut microbiome features showed ties to treatment response and immune-related adverse events in advanced melanoma patients on a combined checkpoint blockade treatment.
Johns Hopkins researchers have developed a single-cell, multispectral imaging platform called AstroPath for precise pathological analysis of cancer specimens.
May 14, 2021
DermTech Q1 Revenues up 62 Percent
May 10, 2021
Castle Biosciences Q1 Revenues Up 31 Percent
Mar 8, 2021
Castle Biosciences Q4 Revenues Down 2 Percent
Jan 19, 2021
OncoHost Raises $8 Million in Series B Funding Round
Dec 23, 2020
Nov 9, 2020